The pharmaceutical industry is distributing talking points, organizing opposition, and even collecting congressional signatures in an attempt to reverse President Joe Biden's support for worldwide access to generic Covid-19 vaccines. The behind-the-scenes moves ... come as the U.S. last week announced that it would support the World Trade Organization proposal, led by India and South Africa, to temporarily waive enforcement of intellectual property and patent rights on coronavirus vaccines. Without a radical expansion in vaccine manufacturing capacity, many developing countries will not achieve mass vaccination rates until 2023 or 2024. The waiver request, which was unexpectedly endorsed by Biden's administration on May 5, is designed to provide legal immunity for drug firms to copy the formulas of existing vaccines to supply low-cost vaccines to low-income countries. On Wednesday, Jared Michaud, a lobbyist with the Pharmaceutical Research and Manufacturers of America, a trade group that represents Pfizer, Johnson & Johnson, AstraZeneca, and other major drug firms, sent an email laying out the industry's role in coaxing lawmakers to push back against a waiver. One of the documents laid out potential national security concerns and suggested that lawmakers should argue the waiver could empower Russia and China. PhRMA ... spent over $24 million on federal lobbying last year and is one of the biggest corporate players in election spending.